Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Repirinast

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Algernon Receives USPTO Allowance For Kidney Disease Patent
    Algernon Receives USPTO Allowance For Kidney Disease Patent

    06 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/06/3004470/0/en/Algernon-Pharmaceuticals-Receives-Notice-of-Allowance-from-USPTO-For-Repirinast-in-Kidney-Disease-Patent.html

    GLOBENEWSWIRE
    06 Jan 2025
    Share Share
    Algernon Receives Notice of Intention to Grant for Repirinast
    Algernon Receives Notice of Intention to Grant for Repirinast

    31 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/01/31/2820948/0/en/Algernon-Pharmaceuticals-Receives-Notice-of-Intention-to-Grant-from-Chinese-Patent-Office-for-Repirinast-to-Treat-CKD.html

    GLOBENEWSWIRE
    31 Jan 2024
    Share Share
    Algernon Pharmaceuticals Receives Notice of Intention to Grant for Repirinast
    Algernon Pharmaceuticals Receives Notice of Intention to Grant for Repirinast

    30 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/30/2788453/0/en/Algernon-Pharmaceuticals-Receives-Notice-of-Intention-to-Grant-from-Chinese-Patent-Office-for-Repirinast-to-Treat-NASH-and-NAFLD.html

    GLOBENEWSWIRE
    30 Nov 2023
    Share Share
    Algernon Pharma Receives Japanese Patent Notice of Allowance for Repirinast
    Algernon Pharma Receives Japanese Patent Notice of Allowance for Repirinast

    08 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/08/2776069/0/en/Algernon-Pharmaceuticals-Receives-Japanese-Patent-Notice-of-Allowance-for-Treatment-of-NASH-with-Repirinast.html

    GLOBENEWSWIRE
    08 Nov 2023
    Share Share
    Algernon Provides Update on Planned PI Repirinast Chronic Kidney Disease Study
    Algernon Provides Update on Planned PI Repirinast Chronic Kidney Disease Study

    11 Jul 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/07/11/2477137/0/en/Algernon-Pharmaceuticals-Provides-Update-on-its-Planned-Phase-1-Repirinast-Chronic-Kidney-Disease-Study.html

    GLOBENEWSWIRE
    11 Jul 2022
    Share Share
    Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast
    Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast

    26 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/26/2428910/0/en/Algernon-Pharmaceuticals-Announces-Lead-Chronic-Kidney-Disease-Drug-Repirinast-Reduced-Fibrosis-by-56-in-a-Preclinical-NASH-Study.html

    GLOBENEWSWIRE
    26 Apr 2022
    Share Share